SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending sharply higher following a strong earnings report that highlighted record user growth, expanding margins, and the success of its Wrapped campaign, sparking community debate over its transition from a pure growth story to a high-margin cash generator. Many users are pointing to impressive premium subscriber increases and improved profitability as reasons for the stock's significant bounce from its recent lows, viewing it as a major turning point.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending amidst widespread user frustration over persistent platform outages and trading restrictions on its ThinkorSwim and mobile apps, leading many to consider alternative brokers, even as the company reports strong financial performance, including a substantial share buyback and strategic acquisitions into private markets.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

The imminent merger vote for Churchill Capital Corp X with Infleqtion, solidified by SEC approval and a clear timeline to trade as INFQ, is fueling significant investor interest. The community widely views Infleqtion as an undervalued leader in quantum technology, citing its robust government and industry partnerships, including with NASA and NVIDIA, and its superior neutral-atom computing, setting the stage for a potential re-rating against its peers.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending due to a significant stock drop after a key potential tenant terminated a $150 million funding agreement for its Project Matador data center, despite management indicating ongoing negotiations and plans to accelerate other client deals. The community is actively debating whether this presents a 

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending as its recent robust earnings beat and impressive high-value client additions are sparking optimism that this could signal a broader recovery for the beleaguered software sector, with many highlighting DDOG's critical role in AI infrastructure.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after Morgan Stanley initiated coverage with an "Overweight" rating and a $37 price target, fueling optimism for its strategic pivot to high-performance computing and data center infrastructure. The community is actively discussing the company's strong power assets and expansion plans, with many anticipating a significant short squeeze.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending after its Q4 earnings report, which, despite an initial sell-off, highlighted strong revenue and GMV growth along with a substantial reduction in cash burn. The community is actively discussing this progress towards profitability by late 2026, viewing the dip as a buying opportunity in the promising African e-commerce market.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing significant upward momentum after announcing positive top-line data from its Phase 2a trial for EVO301 in moderate-to-severe atopic dermatitis, which met its primary efficacy and safety endpoints. The community is actively discussing strong price targets and potential for a short squeeze, though some caution about the company's valuation and debt for a biotech at this clinical stage.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending due to its sweetened bid for Warner Bros. Discovery, which aims to de-risk the acquisition by covering debt and breakup fees amidst growing regulatory scrutiny for Netflix's competing offer, while the community actively discusses the strong subscriber growth from its recent UFC event.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is surging after releasing robust 52-week maintenance data for its atopic dermatitis drug, Rezpeg, showcasing durable efficacy and a clean safety profile. The community is actively discussing the drug's strong competitive positioning, which is further bolstered by recent Nobel Prize recognition validating Treg-based therapies, fueling significant upside potential and buyout speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Tuesday...

Omeros Announces First Commercial Sales of YARTEMLEA

Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers...

Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are covering the firm, Marketbeat reports. One...

Omeros (NASDAQ:OMER) Shares Down 5.8% Following Insider Selling

Omeros (NASDAQ:OMER) Shares Down 5.8% After Insider Selling...

Omeros (NASDAQ:OMER) CAO David Borges Sells 30,000 Shares

Omeros Corporation (NASDAQ:OMER - Get Free Report) CAO David Borges sold 30,000 shares of the company's stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of...

Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares

Omeros Corporation (NASDAQ:OMER - Get Free Report) CAO David Borges sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an...

Omeros (NASDAQ:OMER) Trading Up 10.3% on Analyst Upgrade

Omeros (NASDAQ:OMER) Stock Price Up 10.3% on Analyst Upgrade...

<ul class="summary-bullets"><li>Investors turned cautious ahead of key U.S. jobs data and a potential court ruling on President Donald Trump’s global tariffs expected Friday.&nbsp;</li><li>Retail traders, however, stayed bullish on SPY and QQQ on Stocktwits.</li></ul>U.S. stock futures were lower early Thursday, following a pullback in major indexes. President&nbsp;Donald Trump’s policy comments triggered a late selloff, with defense, financial, and energy stocks under pressure.Investors are also cautious ahead of the big jobs data and the potential US court&nbsp;ruling on Trump’s global tariffs due on Friday.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq 100 futures were down 0.3%, S&amp;P 500 futures and Dow futures were down 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has moved back to ‘bullish’ from ‘extremely bullish’ a day ago, amid high message volumes.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Nvidia (NVDA): The Jensen Huang-led chipmaker is reportedly requiring full upfront payment, with&nbsp;no cancellation rights, for H200 chips from Chinese clients to hedge against regulatory export uncertainty. Microsoft (MSFT): The company’s communications&nbsp;chief took to social media to <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-stock-in-focus-as-fresh-layoff-rumors-swirl/cmUGzFNR4PB">blast rumors</a> of fresh mass layoffs as "100% made up," attempting to steady the stock ahead of the&nbsp;market open. Apple (AAPL):&nbsp;Google parent Alphabet (GOOGL) surpassed Apple in market cap for the first time since 2019, closing at $3.888 trillion on Wednesday. It has also switched its banking partner from Goldman Sachs to JPMorgan, the new issuer of the Apple Card.&nbsp; Nio (NIO):&nbsp;The EV maker announced aggressive 2026 expansion plans for Australia, New Zealand, and Thailand, focusing on right-hand-drive markets to bypass Western tariffs. Applied Digital (APLD)&nbsp;saw a high volume of trading following its massive revenue growth report. Ventyx Biosciences (VTYX):&nbsp;Clear Street analyst downgraded the stock to ‘Hold’ from ‘Buy’ with a price target of $14, up from $11, after Eli Lilly (LLY) agreed to acquire Ventyx for $1.2B. Also, LifeSci Capital downgraded it to ‘Market Perform’ from ‘Outperform’ with a $14 price target.&nbsp; Alumis (ALMS) remains on retail radar following a massive ‘follow-on’ financing move following its recent clinical success. Alumis priced an&nbsp;upsized public offering of 17.65 million shares at&nbsp;$17 per share, aiming to raise&nbsp;$300 million. Elevai Labs (ELAB) popped 8%, and&nbsp;Omeros (OMER) rose 5% in after-hours trading on Wednesday, with Omeros gaining steam following a positive FDA conference call on its drug Yartemlea. U.S. defence stocks will be in focus, driven by&nbsp;Trump’s comments to bump up the military budget.Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;One Stop Systems (OSS), Paramount Skydance (PSKY), IREN Limited (IREN), Momentus (MNTS), and Regencell Bioscience (RGC).Other Catalysts To Watch On the economic front, investors are looking ahead to the release of Initial Jobless Claims (8:30 a.m. ET), which is a crucial indicator ahead of Friday’s big employment report. Traders will also be monitoring the U.S. Trade Deficit &amp; Productivity data (8:30 a.m. ET) and Consumer Credit data (3 p.m. ET) later today.&nbsp; And noteworthy names on the earnings calendar today include Tilray Brands (TLRY), TD Synnex (SNX),&nbsp;Commercial Metals Company (CMC), and&nbsp;Neogen Corporation (NEOG), among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.

Equity

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.


<ul class="summary-bullets"><li>The company set a $36,000 per-vial price for Yartemlea and confirmed the start of its U.S. launch.</li><li>Typical Yartemlea treatment courses use 8–10 vials.</li><li>The U.S. rollout is underway, with initial deliveries expected later this month.</li></ul>Omeros Corp shares rose about 5% in after-hours trading on Wednesday after the company outlined pricing and near-term rollout details for Yartemlea, its newly approved treatment for a rare transplant complication, giving investors clearer visibility into the drug’s early commercial opportunity.<h2 class="st-heading-2">Omeros Puts A Price On Yartemlea</h2>On a special call, Omeros said it has set an initial price of about $36,000 per&nbsp;single-dose&nbsp;vial for Yartemlea, the first and only FDA-approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).TA-TMA is a complication after stem cell transplants where damaged small blood vessels cause clotting that can lead to organ failure.The company said that across the trial and the expanded access program, the median utilization was 8–10 vials per treatment course,&nbsp;which would put the total cost at roughly $288,000 to $360,000 per patient.<h2 class="st-heading-2">US Launch Begins&nbsp;</h2>Omeros said it began the U.S. commercial rollout in early January, with its fully hired and trained commercial team now engaging transplant centers nationwide. The company said it is prioritizing high-volume transplant centers, where early utilization is expected to concentrate.The company said that the drug’s product packaging with the FDA-approved label is underway, with transfer to wholesalers targeted for the third week of January and initial deliveries to transplant centers expected shortly thereafter, supported by a next-day delivery model.Omeros added that recent manufacturing campaigns, existing inventory, and a five-year shelf life are expected to provide sufficient supply into late 2029.<h2 class="st-heading-2">FDA Greenlights Yartemlea</h2>Yartemlea&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-omeros-stock-surging-fda-verdict-this-week/cLesvbHREv7">received FDA approval in late December</a>, becoming the first and only therapy indicated for TA-TMA in adults and children aged two years and older. Approval was based on a single-arm pivotal study of 28 patients, supported by data from an expanded access program involving 221 patients.In those studies, patients treated with Yartemlea achieved complete response rates of 61% in the pivotal trial and 68% in evaluable expanded-access patients, with 100-day survival&nbsp;rates of 73% and 74%, respectively. All patients met international criteria for high-risk TA-TMA, a population with historically poor outcomes.Peer-reviewed publications cited by the company showed treatment with Yartemlea was associated with a three to fourfold lower risk of mortality compared to an external control cohort, with one-year survival of about 50% even in previously refractory high-risk patients, compared with earlier survival rates below 20%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Omeros was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/omerss_png_16d6228853.webp" alt="omerss.png" width="971" height="142"><figcaption>OMER sentiment and message volume as of January 7| Source: Stocktwits</figcaption></figure>One user said the move creates an attractive entry point, adding that they remain confident after the special call and expect further upside, citing potential European partnership news, possible analyst upgrades, and an improving bottom-line outlook.<stembedurl>https://stocktwits.com/minnguy64/message/641160269</stembedurl>Another user called the latest development a “stellar” conference call.<stembedurl>https://stocktwits.com/naturegirl669/message/641155439</stembedurl><a href="https://stocktwits.com/symbol/OMER">Omeros’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Omeros Stock Jump 5% In After-Hours Trading Today?

Yartemlea shipments to wholesalers are expected in the third week of January.

Omeros (NASDAQ:OMER) Trading Down 6% - Should You Sell?

Omeros (NASDAQ:OMER) Shares Down 6% - Should You Sell...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Current Price	$11.44
Prev Close	$11.30
Open	$11.34
Dividend Yield	0.00%
50-Day Moving Average	$11.92
Beta	1.53
Avg. Volume	2.63M
PE Ratio	-5.60

52-Week High	$17.65
52-Week Low	$2.95
Market Capitalization	$801.18M
EPS (Annual)	-$2.70
Price to Book	-3.59
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OMER News

OMEROmeros Corp